Despite the availability of several new systemic agents for psoriasis treatment, choosing the
right therapy in certain patient populations can be challenging. There are few up-to-date …

The use of biological agents and immunomodulators for inflammatory bowel disease (IBD)
has remarkably improved disease management in the current era but at the same time has …

Psoriasis is a common disease, which has a considerable impact on the healthcare system.
Therefore, appropriate use of therapeutic resources is very important. Management of …

Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …

Tumor necrosis factor-α (TNF-α) inhibitors are known to increase reactivation of concurrent
chronic hepatitis B, but their impact on the hepatitis C virus (HCV) is controversial. Some …

Objective The aim of this study was to assess the effects of anti‐tumor necrosis factor (TNF)
agents or disease‐modifying antirheumatic drugs (DMARD s) on hepatitis B virus (HBV) …

Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …

Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the
world's population. Systemic treatments, including methotrexate and cyclosporin, are …

Introduction. Antitumor necrosis factor-alpha (TNF-α) agents are widely used for treatment of
rheumatic and dermatological diseases. We conducted the systematic review and meta …

Abstract Background and Objectives Ustekinumab is used to treat moderate-to-severe
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …